Evaluation of anaphylactic reaction as an adverse event for perindopril erbumine tablets

Authors

  • Kiran Krishnan Department of Pharmacy Annamalai University Chidambaram, Tamil Nadu
  • Kathiresan Krishnasamy Department of Pharmacy Annamalai University Chidambaram, Tamil Nadu

DOI:

https://doi.org/10.3329/icpj.v3i4.18265

Keywords:

Angiotensin-converting enzyme, coronary artery disease, hypertension, perindoprilat, system organ class, tert-butylamine salt

Abstract

Perindopril erbumine is a tert-butylamine salt of perindopril used in the treatment of stable coronary artery disease and hypertension. The present study was aimed to evaluate the anaphylactic reaction as an adverse event for perindopril erbumine tablets. Electronic extraction of data from the safety database for this report includes all cases of anaphylactic reaction where perindopril was a primary or co-suspect drug. The study result have shown that there were overall 205 case reports for perindopril in the database, of which 200 cases were assessed as (potentially) perindopril and 05 were assessed as non-perindopril product. From the 200 case reports, 141 were serious and 59 were non-serious. Out of the 141 serious cases, 137 cases were medically confirmed while remaining 04 cases were consumer reports. Of the total 205 case reports there were five cases wherein the patient experienced anaphylactic reaction. The study concludes that three out of five cases entered in the drug safety database suggestive of a possible association between perindopril and anaphylactic reaction.

DOI: http://dx.doi.org/10.3329/icpj.v3i4.18265

International Current Pharmaceutical Journal, March 2014, 3(4): 254-258

Downloads

Download data is not yet available.
Abstract
175
PDF
137

Downloads

Published

2014-03-07

How to Cite

Krishnan, K., & Krishnasamy, K. (2014). Evaluation of anaphylactic reaction as an adverse event for perindopril erbumine tablets. International Current Pharmaceutical Journal, 3(4), 254–258. https://doi.org/10.3329/icpj.v3i4.18265

Issue

Vol. 3 No. 4 (2014)

Section

Original Articles

License

Authors who publish with this journal agree to the following terms:

  1. The journal holds copyright and publishes the work under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).